Rosiglitazone and Liver Failure

Letters5 September 2000Rosiglitazone and Liver FailureWilliam L. Isley, MD and Julie C. Oki, PharmDWilliam L. Isley, MDUniversity of Missouri; Kansas City, MO 64111 (Isley, Oki)Search for more papers by this author and Julie C. Oki, PharmDUniversity of Missouri; Kansas City, MO 64111 (Isley, Oki)Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-133-5-200009050-00022 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We read with interest the recent reports of hepatic dysfunction associated with the use of rosiglitazone (1, 2). According to the classification scheme of Naranjo and colleagues (3), both reports would at most suggest a possible association with the administration of rosiglitazone because of other confounding factors. The liver abnormalities in the case presented by Forman and colleagues (1) may be related to hypotension, as hypothesized by Freid and coworkers in an accompanying letter (4). The case presented by Al-Salman and associates (2) is clouded by a history of alcohol abuse, acetaminophen use, and concomitant administration of ...References1. Forman LM, Simmons DA, Diamond RH. Hepatic failure in a patient taking rosiglitazone. Ann Intern Med. 2000;132:118-21. LinkGoogle Scholar2. Al-Salman J, Arjomand H, Kemp DG, Mittal M. Hepatocellular injury in a patient receiving rosiglitazone. A case report. Ann Intern Med. 2000;132:121-4. LinkGoogle Scholar3. Naranjo CA, Busto U, Sellers M, Sandor P, Ruiz I, Roberts EA, et al . A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther. 1981;30:239-45. CrossrefMedlineGoogle Scholar4. Freid J, Everitt D, Boscia J. Rosiglitazone and hepatic failure [Letter]. Ann Intern Med. 2000;132:164. LinkGoogle Scholar5. Neuschwander-Tetri BA, Isley WL, Oki JC, Ramrakhiani S, Quiason SG, Phillips NJ, et al . Troglitazone-induced hepatic failure leading to liver transplantation. A case report. Ann Intern Med. 1998;129:38-41. LinkGoogle Scholar Author, Article, and Disclosure InformationAuthors: William L. Isley, MD; Julie C. Oki, PharmDAffiliations: University of Missouri; Kansas City, MO 64111 (Isley, Oki) PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoHepatic Failure in a Patient Taking Rosiglitazone Lisa M. Forman , David A. Simmons , and Robert H. Diamond Hepatocellular Injury in a Patient Receiving Rosiglitazone: A Case Report Jameela Al-Salman , Heider Arjomand , David G. Kemp , and Manoj Mittal Rosiglitazone and Hepatic Failure Jeffrey Freid , Daniel Everitt , and Jerome Boscia Rosiglitazone and Liver Failure Lisa M. Forman and Robert H. Diamond Metrics Cited byCharacterizing the mechanism of thiazolidinedione-induced hepatotoxicity: An in vitro model in mitochondriaExamining the safety of PPAR agonists – current trends and future prospectsHepatic injury due to drugs, herbal compounds, chemicals and toxinsTroglitazoneDephosphorylation of ribosomal protein P0 in response to troglitazone-induced cytotoxicitySecond-Generation Thiazolidinediones and HepatotoxicityHepatotoxicity of thiazolidinedionesThiazolidinediones – some recent developmentsLeukotriene antagonistsIdentification of glutathione conjugates of troglitazone in human hepatocytesEffects of Pioglitazone and rosiglitazone on blood lipid levels and glycemic control in patients with type 2 diabetes mellitus: A retrospective review of randomly selected medical recordsGlitazones: clinical effects and molecular mechanismsHepatotoxicity of thiazolidinedionesLiver failure in a patient treated with long-term rosiglitazone therapyDrug-induced liver disease 5 September 2000Volume 133, Issue 5Page: 393KeywordsAcute liver failureAlcoholismHypotensionLiverMetabolic pathwaysVitamin E ePublished: 5 September 2000 Issue Published: 5 September 2000 Copyright & PermissionsCopyright © 2000 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...